Servier Joins Embleema’s Blockchain Health Consortium to Launch a Pilot Project for Blockchain

Fibo Quantum

PARIS–()–Servier, an independent international pharmaceutical company, announced
today that it has joined Embleema’s Blockchain Health Consortium, a
decentralized network based on Blockchain technology, as part of the
launch of a pilot blockchain project within the Group. Embleema’s
Blockchain Health Consortium, which brings together patient
associations, life sciences companies and healthcare professionals,
offers patients the opportunity to share digital health data in real
time to inform clinical research, enabling better patient engagement and
monitoring of their data in real life.

As part of the consortium, Servier will contribute to the construction
of the Embleema Blockchain decentralized network, hosting a hub on its
servers to securely store and share data, and operate the network to
guarantee the safety of sensitive data. This pilot project will run for
one year and aims to define and evaluate an operational process before
considering deployment of the technology on a larger scale.

“A considerable amount of health data is generated every day, including
by patients themselves via, for example, connected objects. This data is
an invaluable source of knowledge to accelerate the discovery of new
therapeutic solutions. In this context, the Blockchain is seen as a key
technology in the creation of a more collaborative model between
healthcare professionals and patients,” commented Olivier Laureau,
President of Servier. “This is why we are excited to contribute, within
the Embleema Health Blockchain Consortium, to the construction of this
new model which reflects the commitment of the Group to put patient
needs at the center of all its activities.”

Robert Chu, CEO of Embleema added: “Embleema’s health blockchain enables
patients to own their data, and allows for better accessibility and
transparency of real world data to accelerate drug development and
ultimately bring more personalized therapies to patients sooner. We are
delighted to welcome Servier to our Health Blockchain Consortium, and
look forward to our collaboration to improve patient engagement and data

The Consortium’s aims align with the objectives outlined by the 21st
Century Cures Act, a healthcare bill signed into U.S. law in 2016, which
grants the FDA a mandate to accelerate regulatory approval for new
treatments that incorporate the perspectives of patients and real world
evidence data reporting. This has led life sciences companies to
integrate real world evidence (RWE) into clinical studies, which include
Electronic Health Records (EHR), patient reported outcomes and connected
health sensors.

About Servier

Servier is an international pharmaceutical company governed by a
non-profit foundation, with its headquarters in France (Suresnes). With
a strong international presence in 149 countries and a turnover of 4.152
billion euros in 2017, Servier employs 21,700 people worldwide. Entirely
independent, the Group reinvests 25% of its turnover (princeps drugs) in
research and development and uses all its profits for development.
Corporate growth is driven by Servier’s constant search for innovation
in five areas of excellence: cardiovascular, immune-inflammatory and
neuropsychiatric diseases, cancer and diabetes, as well as by its
activities in high-quality generic drugs. Servier also offers eHealth
solutions beyond drug development.

More information:

Follow us on Social Media: LinkedIn,

About Embleema

Embleema is
the patient-driven healthcare blockchain network for secure sharing of
personal health records. Hosted on a private Ethereum blockchain,
Embleema’s consolidated, highly-secure repository provides the
healthcare ecosystem with an undisputed and holistic view of patients’
medical history, Embleema is creating a decentralized healthcare data
economy by connecting the key stakeholders in the healthcare industry,
directly with patients while maintaining the patient’s data sovereignty.

For more information, please visit and
follow Embleema on Twitter @EmbleemaTelegramLinkedIn,
and Facebook.